Press release
Herpes Simplex Market to Expand Significantly by 203, States DelveInsight Report | GlaxoSmithKline, ModernaTX, Maruho Co., Bioalliance Pharma/Vectans Pharma, Novartis, Maruho Co
DelveInsight's "Herpes Simplex Market Insights, Epidemiology, and Market Forecast-2034 report offers an in-depth understanding of the Herpes Simplex, historical and forecasted epidemiology as well as the Herpes Simplex market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the Herpes Simplex market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Herpes Simplex Market Forecast [https://www.delveinsight.com/sample-request/herpes-simplex-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Some of the key facts of the Herpes Simplex Market Report:
*
The Herpes Simplex market size was valued ~USD 3,159 million in 2023 and is anticipated to grow with a significant CAGR during the study period (2020-2034)
*
In September 2024, GSK has announced that Part II of the Phase I/II TH HSV REC-003 trial for its therapeutic herpes simplex virus (HSV) vaccine candidate, GSK3943104, failed to achieve its primary efficacy endpoint. This conclusion was drawn from an analysis of the primary objective data from the Phase II segment of the trial. Designed to offer a new therapeutic option for HSV, GSK3943104 will not be advanced to Phase III studies following the trial results.
*
As per DelveInsight's analysis, the United States held the largest market share for Herpes Simplex in the 7MM, with a market size of USD 1,590 million in 2023.
*
In 2023, Germany led the EU4 with the largest market size for Herpes Simplex at USD 320 million, followed by the UK at USD 282 million, while Spain had the smallest market size at USD 173 million.
*
According to estimates, Japan's market size for Herpes Simplex was around USD 349 million in 2023, with expectations of growth throughout the forecast period.
*
In 2023, the total diagnosed cases of Herpes Simplex in the 7MM were approximately 13,038 thousand. These cases are projected to rise over the study period from 2020 to 2034.
*
According to DelveInsight's estimates, the United States accounted for approximately 38% of the total diagnosed prevalent cases of Herpes Simplex in the 7MM in 2023.
*
In 2023, gender-specific cases of Herpes Simplex in the EU4 and the UK were roughly 45% male and 55% female. These cases are expected to decline over time.
*
In 2023, Germany had the highest number of prevalent Herpes Simplex cases among the EU4 and the UK, followed by the UK, which recorded approximately 1,511 thousand cases.
*
In 2023, recurrent herpes simplex cases in Japan showed that HSV-2 accounted for more than 67%, while HSV-1 made up 33%.
*
Key Herpes Simplex Companies: Labo'Life, AiCuris Anti-infective Cures AG, GlaxoSmithKline, ModernaTX, Inc., Maruho Co., Ltd., Bioalliance Pharma/Vectans Pharma, Novartis, Maruho Co., Ltd., Beech Tree Labs, Inc., and others
*
Key Herpes Simplex Therapies: 2LHERP Registered , Pritelivir, GSK3943104, mRNA-1608, AMENALIEF (amenamevir), SITAVIG (acyclovir), famciclovir, ASP2151, BTL TML HSV, and others
*
The Herpes Simplex market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Herpes Simplex pipeline products will significantly revolutionize the Herpes Simplex market dynamics.
Herpes Simplex Overview
Herpes Simplex is a viral infection caused by the herpes simplex virus (HSV). It comes in two forms: HSV-1, which primarily causes oral herpes (cold sores), and HSV-2, which typically causes genital herpes. Both types can cause sores or blisters at the infection site and are transmitted through direct contact with the infected areas or bodily fluids. While there is no cure for herpes, antiviral treatments can help manage symptoms and reduce the risk of transmission. The virus can remain dormant in the body and reactivate periodically, causing recurrent outbreaks.
Get a Free sample for the Herpes Simplex Market Forecast, Size & Share Analysis Report:
https://www.delveinsight.com/report-store/herpes-simplex-market [https://www.delveinsight.com/report-store/herpes-simplex-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Herpes Simplex Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
Herpes Simplex Epidemiology Segmentation:
The Herpes Simplex market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:
*
Total Seroprevalence of HSV in the 7MM
*
Total Symptomatic Cases of HSV in the 7MM
*
Total Diagnosed Cases of HSV in the 7MM
*
Gender-specific Diagnosed Cases of HSV in the 7MM
*
Total Recurrent Cases of HSV in the 7MM
Download the report to understand which factors are driving Herpes Simplex epidemiology trends @ Herpes Simplex Epidemiology Forecast [https://www.delveinsight.com/sample-request/herpes-simplex-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Herpes Simplex Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Herpes Simplex market or expected to get launched during the study period. The analysis covers Herpes Simplex market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Herpes Simplex Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Herpes Simplex Therapies and Key Companies
*
2LHERP Registered : Labo'Life
*
Pritelivir: AiCuris Anti-infective Cures AG
*
GSK3943104: GlaxoSmithKline
*
mRNA-1608: ModernaTX, Inc.
*
AMENALIEF (amenamevir): Maruho Co., Ltd.
*
SITAVIG (acyclovir): Bioalliance Pharma/Vectans Pharma
*
famciclovir: Novartis
*
ASP2151: Maruho Co., Ltd.
*
BTL TML HSV: Beech Tree Labs, Inc.
Discover more about therapies set to grab major Herpes Simplex market share @ Herpes Simplex Treatment Landscape [https://www.delveinsight.com/sample-request/herpes-simplex-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Herpes Simplex Market Strengths
*
The increase in healthcare expenditure in developing countries has increased access to healthcare services, including HSV treatment. This has increased the access to healthcare and surged the demand for herpes simplex virus treatment.
*
The chronic and recurrent nature of HSV infections creates a sustained need for ongoing care and treatment options in the market.
Herpes Simplex Market Opportunities
*
Collaboration between research institutes and healthcare sectors will immensely boost the market and its potential to make better curative therapies than existing palliative care.
*
Raising public awareness for herpes simplex infections can result in an earlier diagnosis and initiation of therapy ultimately boosting the financial state.
Scope of the Herpes Simplex Market Report
*
Study Period: 2020-2034
*
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
*
Key Herpes Simplex Companies: Labo'Life, AiCuris Anti-infective Cures AG, GlaxoSmithKline, ModernaTX, Inc., Maruho Co., Ltd., Bioalliance Pharma/Vectans Pharma, Novartis, Maruho Co., Ltd., Beech Tree Labs, Inc., and others
*
Key Herpes Simplex Therapies: 2LHERP Registered , Pritelivir, GSK3943104, mRNA-1608, AMENALIEF (amenamevir), SITAVIG (acyclovir), famciclovir, ASP2151, BTL TML HSV, and others
*
Herpes Simplex Therapeutic Assessment: Herpes Simplex current marketed and Herpes Simplex emerging therapies
*
Herpes Simplex Market Dynamics: Herpes Simplex market drivers and Herpes Simplex market barriers
*
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
*
Herpes Simplex Unmet Needs, KOL's views, Analyst's views, Herpes Simplex Market Access and Reimbursement
To know more about Herpes Simplex companies working in the treatment market, visit @ Herpes Simplex Clinical Trials and Therapeutic Assessment [https://www.delveinsight.com/sample-request/herpes-simplex-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Table of Contents
1. Herpes Simplex Market Report Introduction
2. Executive Summary for Herpes Simplex
3. SWOT analysis of Herpes Simplex
4. Herpes Simplex Patient Share (%) Overview at a Glance
5. Herpes Simplex Market Overview at a Glance
6. Herpes Simplex Disease Background and Overview
7. Herpes Simplex Epidemiology and Patient Population
8. Country-Specific Patient Population of Herpes Simplex
9. Herpes Simplex Current Treatment and Medical Practices
10. Herpes Simplex Unmet Needs
11. Herpes Simplex Emerging Therapies
12. Herpes Simplex Market Outlook
13. Country-Wise Herpes Simplex Market Analysis (2020-2034)
14. Herpes Simplex Market Access and Reimbursement of Therapies
15. Herpes Simplex Market Drivers
16. Herpes Simplex Market Barriers
17. Herpes Simplex Appendix
18. Herpes Simplex Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=herpes-simplex-market-to-expand-significantly-by-203-states-delveinsight-report-glaxosmithkline-modernatx-maruho-co-bioalliance-pharmavectans-pharma-novartis-maruho-co]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Herpes Simplex Market to Expand Significantly by 203, States DelveInsight Report | GlaxoSmithKline, ModernaTX, Maruho Co., Bioalliance Pharma/Vectans Pharma, Novartis, Maruho Co here
News-ID: 3997748 • Views: …
More Releases from ABNewswire
Rotator Cuff Injuries Market Poised for Significant Growth by 2032, Driven by In …
The rotator cuff injuries treatment market is expected to witness substantial growth, primarily fueled by an increasing prevalence, an aging population, advancements in minimally invasive surgical techniques, and the emergence of novel biologic therapies. Key rotator cuff repair companies, including Ortho Regenerative Technologies, Angiocrine Bioscience, Smith & Nephew, Arcuro Medical, and Atreon Orthopedics, are at the forefront of innovation, addressing the significant unmet needs.
DelveInsight's "Rotator Cuff Injuries Market Insights, Epidemiology,…
Lumbar Spondylolisthesis Treatment Market Projected to Witness Significant Growt …
The lumbar spondylolisthesis market is expected to demonstrate a promising CAGR by 2032. This growth trajectory is primarily fueled by increasing prevalence across aging populations, enhanced diagnostic capabilities, and a robust pipeline of novel therapeutic approaches by key spondylolisthesis companies including Abbott, Medtronic, Stryker, Johnson & Johnson, Zimmer Biomet, Globus Medical, NuVasive, and Orthofix leading innovation in both conservative management and surgical interventions.
DelveInsight's "Lumbar Spondylolisthesis - Market Insight, Epidemiology And…
HER2-Positive Breast Cancer Market Projected for Substantial Growth Through 2032 …
The HER2-positive breast cancer treatment market is witnessing significant expansion, driven by the emergence of novel targeted therapies, antibody-drug conjugates, and innovative treatment approaches by key breast cancer companies, including Roche, Daiichi Sankyo, AstraZeneca, Seagen, Gilead Sciences, Macrogenics, Zymeworks, Puma Biotechnology, Jazz Pharmaceuticals, among others.
DelveInsight's "HER2-Positive Breast Cancer - Market Insight, Epidemiology And Market Forecast - 2032 [https://www.delveinsight.com/report-store/her2-positive-breast-cancer-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr]" report provides comprehensive insights into the historical and forecasted HER2-positive breast cancer…
Myelodysplastic Syndrome with Excess Blasts-2 Treatment Market Expected to Stren …
The Myelodysplastic Syndrome with Excess Blasts-2 market is anticipated to witness substantial growth across the 7MM (United States, EU4, United Kingdom, and Japan) by 2032, primarily driven by rising disease awareness, improved diagnostic capabilities, and the development of innovative therapeutic interventions by key MDS-EB2 companies, including Sunesis Pharmaceuticals, Astellas Pharma Global Development Inc., Jazz Pharmaceuticals, Celgene, and Access Pharmaceuticals Inc., among others.
DelveInsight's "Myelodysplastic Syndrome with Excess Blasts2 Market Insight, Epidemiology…
More Releases for Herpes
Global Herpes Labialis (Oral Herpes) Drugs Market Future Analysis Report 2018-20 …
This report studies the global market size of Herpes Labialis (Oral Herpes) Drugs in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Herpes Labialis (Oral Herpes) Drugs in these regions.
This research report categorizes the global Herpes Labialis (Oral Herpes) Drugs market by players/brands, region, type and application. This report also studies the global market status, competition…
Drugs for Herpes Labialis (Oral Herpes) Market: GSK, Novartis, Teva, Mylan
HTF MI recently broadcasted a new study in its database that highlights the in-depth market analysis with future prospects of Drugs for Herpes Labialis (Oral Herpes) market. The study covers significant data which makes the research document a handy resource for managers, industry executives and other key people get ready-to-access and self-analyzed study along with graphs and tables to help understand market trends, drivers and market challenges. Some of the…
Global Herpes Labialis (Oral Herpes) Clinical Trials Assessment & Evaluation, H2 …
Market Research Hub (MRH) has include a fresh report to its database titled “Herpes Labialis (Oral Herpes) Global Clinical Trials Review, H2, 2017”, an overview of trial numbers along with the average enrollment in major countries conducted across the globe. Furthermore, the report also presents prominent drugs for in-progress trials based on the count of ongoing trails.
Request Free Sample Report@ https://www.marketresearchhub.com/enquiry.php?type=S&repid=1350157
Oral herpes is a type of infection which occurs on…
Worldwide Herpes Labialis (Oral Herpes) Drugs Information and Market Trend Resea …
Global Herpes Labialis (Oral Herpes) Drugs Market Research Report 2017"" The Report covers current Industries Trends, Worldwide Analysis, Global Forecast, Review, Share, Size, Growth, Effect.
Description-
In this report, the global Herpes Labialis (Oral Herpes) Drugs market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022.
Geographically, this report is segmented…
Global Drugs For Herpes Labialis (Oral Herpes) Market 2017 - Teva, Mylan, Cadila …
Apex Market Reports, recently published a detailed market research study focused on the "Drugs For Herpes Labialis (Oral Herpes) Market" across the global, regional and country level. The report provides 360° analysis of "Drugs For Herpes Labialis (Oral Herpes) Market" from view of manufacturers, regions, product types and end industries. The research report analyses and provides the historical data along with current performance of the global Drugs For…
Drugs for Herpes Labialis (Oral Herpes) Market 2017- Teva, Apotex, Cadila, Mylan …
Apex Research, recently published a detailed market research study focused on the "Drugs for Herpes Labialis (Oral Herpes) Market" across the global, regional and country level. The report provides 360° analysis of "Drugs for Herpes Labialis (Oral Herpes) Market" from view of manufacturers, regions, product types and end industries. The research report analyses and provides the historical data along with current performance of the global Drugs for Herpes Labialis (Oral…
